GSK spinout NeRRe splits the pipeline, creates its own spinout
Five years after NeRRe Therapeutics spun out of GSK with some of its unwanted work in neurosciences, the UK biotech is executing a spinout of its own.
NeRRe has taken a neurokinin-1,3 receptor antagonist — with potential as a hormone replacement therapy — and hived it off into a new biotech called KaNDy Therapeutics. Now KaNDy will take it into a Phase IIb study for postmenopausal vasomotor symptoms.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.